Cited by 615Immunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity

Open access

Ferris, Stephen T., Durai, Vivek, Wu, Renee, Theisen, Derek J., Ward, Jeffrey P., Bern, Michael D., Davidson, Jesse T., Bagadia, Prachi, Liu, Tiantian, Briseño, Carlos G., Li, Lijin, Gillanders, William E., Wu, Gregory F., Yokoyama, Wayne M., Murphy, Theresa L., Schreiber, Robert D., Murphy, Kenneth M.·2020·Nature

DOI 10.1038/s41586-020-2611-3PMC PMC7469755

Open this paper in CoChat — free account

Abstract

Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells 2,3, whereas cDC2 are specialized for priming CD4+ T cells 4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms 6-11, including a process whereby CD4+ T cells 'license' cDC1 for CD8+ T cell priming 12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1 Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2611-3

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, É., Tussiwand, R., & Yona, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3712 · Cited by 1,923
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,454
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213

Show all 50 references

Sorted by citations

Items 201–300 of 615

Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23
Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4+T cell activation in breast cancer
Chen, X., Ma, C., Li, Y., Liang, Y., Chen, T., Han, D., Luo, D., Zhang, N., Zhao, W., Wang, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06944-8 · Cited by 25
Ubiquitination in cancer: mechanisms and therapeutic opportunities
Zhu, S., Zhang, X., Liu, W., Zhou, Z. G., Xiong, S., Li, J., Chen, X., & Peng, C. (2025) · 癌症：英文版 · doi:10.1002/cac2.70044 · Cited by 25
The liver contains distinct interconnected networks of CX3CR1 + macrophages, XCR1 + type 1 and CD301a + type 2 conventional dendritic cells embedded within portal tracts
English, K., Tan, S. Y., Kwan, R. Y. Q., Holz, L. E., Sierro, F., McGuffog, C., Kaisho, T., Heath, W. R., MacDonald, K. P. A., McCaughan, G. W., et al. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12559 · Cited by 21
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
Vienot, A., Jacquin, M., Rebucci-Peixoto, M., Pureur, D., Ghiringhelli, F., Assénat, E., Hammel, P. R., Rosmorduc, O., Stouvenot, M., Allaire, M., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11065-0 · Cited by 23
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors
Wijfjes, Z., van Dalen, F. J., Gall, C. M. L., & Verdoes, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00330 · Cited by 23
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 28
Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
Jin, F., Xie, L., Zhang, H., Fan, X., Tian, J., Liu, W., Xiao, Y., & Fan, X. (2025) · MedComm · doi:10.1002/mco2.70455 · Cited by 29
mRNA vaccines engage unconventional pathways in CD8+ T cell priming
Jo, S., Li, L., Thakur, C., Telfer, K. A., Sultan, H., Ohara, R. A., He, M., Nam, G., Chen, J., Ou, F., et al. (2026) · Nature · doi:10.1038/s41586-026-10353-6 · Cited by 25
IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease
Li, N., Steiger, S., Fei, L., Li, C., Shi, C., Salei, N., Schraml, B. U., Zheng, Z., Anders, H., & Lichtnekert, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685559 · Cited by 22
Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis
Sasaki, I., Kato, T., Hemmi, H., Fukuda‐Ohta, Y., Wakaki-Nishiyama, N., Yamamoto, A., & Kaisho, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857954 · Cited by 22
Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity
Singh, A., & Ranjan, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141712 · Cited by 22
Mgl2+ cDC2s coordinate fungal allergic airway type 2, but not type 17, inflammation in mice
Cook, P. C., Brown, S. L., Houlder, E. L., Furlong-Silva, J., Conn, D. P., Colombo, S. A. P., Baker, S. M., Svedberg, F. R., Howell, G. J., Bertuzzi, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55663-3 · Cited by 24
Recent progress in type 1 classical dendritic cell cross-presentation - cytosolic, vacuolar, or both?
Ohara, R. A., & MURPHY, K. M. M. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102350 · Cited by 21
Shared pathway of WDFY4-dependent cross-presentation of immune complexes by cDC1 and cDC2
Jo, S., Ohara, R. A., Theisen, D. J., Kim, S. K., Liu, T., Bullock, C. B., He, M., Ou, F., Chen, J., Piersma, S. J., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20240955 · Cited by 21
Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors
Mauvais, F., Hamel, Y., Silvin, A., Mulder, K., Hildner, K., Akyol, R., Dalod, M., Koumantou, D., Saveanu, L., Garfa‐Traoré, M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.027 · Cited by 21
Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment
Chen, J., Hu, S., Wang, H., Zhao, T., Song, Y. Q., Zhong, X., Luo, Q., Xu, M., He, L., Chen, Q., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14319-2 · Cited by 21
Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics
Chu, X., Zhang, Y., & Cheng, S. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.06.01 · Cited by 21
Neoadjuvant chemotherapy enhances anti-tumor immune response of tumor microenvironment in human esophageal squamous cell carcinoma
Okuda, S., Ohuchida, K., Nakamura, S., Tsutsumi, C., Hisano, K., Mochida, Y., Kawata, J., Ohtsubo, Y., Shinkawa, T., Iwamoto, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106480 · Cited by 21
Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
Abascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 23
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 22
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancerPreprint
Mattiuz, R., Boumelha, J., Hamon, P., Bérichel, J. L., Vaidya, A. B., Soong, B. Y., Halász, L., Radkevich, E., Kim, H. M., Park, M. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.27.628014 · Cited by 21
Immunometabolism of dendritic cells in health and disease
Guo, C., & Chi, H. (2023) · Advances in immunology · doi:10.1016/bs.ai.2023.10.002 · Cited by 21
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity
Zitti, B., Duval, F., Wirapati, P., Hicham, M., Xie, Y., Oh, J., Hoelzl, J., Meiser, P., Varrone, M., Peterson, H. M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.11.020 · Cited by 22
A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
El-Sayes, N., Vito, A., Salem, O., Workenhe, S. T., Wan, Y., & Mossman, K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031754 · Cited by 20
Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
Cao, Y., Li, Y., Liu, R., Zhou, J., & Wang, K. (2023) · Cancers · doi:10.3390/cancers15092568 · Cited by 22
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
Nguyen, K. B., Roerden, M., Copeland, C., Backlund, C. M., Klop-Packel, N. G., Remba, T. K., Kim, B., Singh, N. K., Birnbaum, M. E., Irvine, D. J., et al. (2023) · eLife · doi:10.7554/elife.85263 · Cited by 20
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
Luri‐Rey, C., Gomis, G., Glez‐Vaz, J., Manzanal, A., Riaño, A. M., Rodriguez-Ruiz, M. E., Teijeira, Á., & Melero, I. (2023) · Immunological Reviews · doi:10.1111/imr.13281 · Cited by 23
The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?
Ghorbaninezhad, F., Nour, M. A., Farzam, O. R., Saeedi, H., Vanan, A. G., Bakhshivand, M., Jafarlou, M., Hatami‐Sadr, A., & Baradaran, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189281 · Cited by 26
The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer
Busselaar, J., Sijbranda, M., & Borst, J. G. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106938 · Cited by 21
Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma
Ruiz‐Torres, D. A., Bryan, M. E., Hirayama, S., Merkin, R. D., Luciani, E. G., Roberts, T. J., Patel, M. J., Park, J. C., Wirth, L. J., Sadow, P. M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2466308 · Cited by 19
Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity
You, Z., Kim, J., Guo, C., Hu, H., Chapman, N. M., Meng, X., Shi, H., Wang, Y., Guy, C. S., Anil, K. C., et al. (2026) · Science · doi:10.1126/science.adv6582 · Cited by 22
Integrating CD4 + T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model
Shibata, H., Xu, N., Saito, S., Zhou, L., Ozgenc, I., Webb, J., Fu, C., Zolkind, P., Egloff, A. M., & Uppaluri, R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1958589 · Cited by 19
Dendritic cell functions in vivo: A user's guide to current and next‐ generation mutant mouse models
Dalod, M., & Scheu, S. (2022) · European Journal of Immunology · doi:10.1002/eji.202149513 · Cited by 19
The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients
Liu, A., Xia, Y., Li, W., Zhang, G., Liu, Y., Ye, S., Zhao, Z.-R., Yang, Y., Jia, Y., Guo, Y., et al. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/3444360 · Cited by 19
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
Schaettler, M. O., Desai, R. R., Wang, A. Z., Livingstone, A. J., Kobayashi, D. K., Coxon, A. T., Bowman-Kirigin, J. A., Liu, C. J., Mao, L., Bender, D. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006121 · Cited by 21
Factor VIII Trafficking to CD4+ T cells Shapes its Immunogenicity and Requires Several Types of Antigen Presenting Cells
Kaczmarek, R., Piñeros, A. R., Patterson, P. E., Bertolini, T. B., Perrin, G. Q., Sherman, A., Born, J., Arisa, S., Arvin, M. C., Kamocka, M. M., et al. (2023) · Blood · doi:10.1182/blood.2022018937 · Cited by 19
Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101239 · Cited by 19
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities
Johnson, P. C., Rosendahl, N., & Radford, K. J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.1994943 · Cited by 18
Radiotherapy-immunomodulated nanoplatform triggers both hypoxic and normoxic tumor associated antigens generation for robust abscopal effect and sustained immune memory
Li, J., Tan, C.-F., Yang, J., Xiang, Z., Wang, Y., Shen, M., Zhu, S., He, T., Liang, X., Shao, B., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123005 · Cited by 18
CD4+ T cell dysfunction in cancer
Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 19
Antigen-presenting cells as arbiters of mucosal tolerance and immunity
Hölting, T. L. B., Park, T., & Brown, C. C. (2025) · Nature Immunology · doi:10.1038/s41590-025-02320-6 · Cited by 22
Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model
Lu, R., Wang, S., Jiang, S., Li, C., Wang, Y., Li, L., Wang, Y., Ma, G., Qiao, H., Leng, Z., et al. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13177 · Cited by 17
MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids
Pickles, O. J., Wanigasooriya, K., Ptasinska, A., Patel, A. J., Robbins, H. L., Bryer, C., Whalley, C., Tee, L. J., Lal, N., Pinna, C. M. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0091 · Cited by 18
A synthetic biology approach to engineering circuits in immune cells
Hoces, D., Blanco, J. M., & Hernández-López, R. A. (2023) · Immunological Reviews · doi:10.1111/imr.13244 · Cited by 19
SYK ubiquitination by CBL E3 ligases restrains cross-presentation of dead cell-associated antigens by type 1 dendritic cells
Henry, C. M., Castellanos, C. A., Buck, M. D., Giampazolias, E., Frederico, B., Cardoso, A., Rogers, N. C., Schulz, O., Lee, S., Canton, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113506 · Cited by 19
Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 18
The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors
Blair, T. C., Alice, A. F., Zebertavage, L., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653625 · Cited by 19
Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses
Twilhaar, M. K. N., Czentner, L., Bouma, R. G., Olesek, K., Grabowska, J. A., Wang, A. Z., Affandi, A. J., Belt, S. C., Kalay, H., van Nostrum, C. F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842241 · Cited by 17
Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer
Burrack, A. L., Schmiechen, Z. C., Patterson, M. T., Miller, E. A., Spartz, E. J., Rollins, M. R., Raynor, J. F., Mitchell, J. S., Kaisho, T., Fife, B. T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151593 · Cited by 17
WDFY4 deficiency in NOD mice ameliorates autoimmune diabetes and insulitis
Ferris, S. T., Liu, T., Chen, J., Ohara, R. A., Ou, F., Wu, R., Kim, S. K., Murphy, T. L., & MURPHY, K. M. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219956120 · Cited by 17
The role of dendritic cells in radiation-induced immune responses
Kaur, A. P., Alice, A. F., Crittenden, M. R., & Gough, M. J. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.02.002 · Cited by 18
Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment
Cheng, H., Chen, W., Lin, Y., Zhang, J., Song, X., & Zhang, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00125-3 · Cited by 22
Role of mouse dendritic cell subsets in priming naive CD4 T cells
Tatsumi, N., & Kumamoto, Y. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102352 · Cited by 17
Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment
Luo, W., Wang, J., Chen, H., Qiu, J., Wang, R., Liu, Y., Su, D., Tao, J., Weng, G., Ma, H., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216423 · Cited by 17
Batf3-dependent orchestration of the robust Th1 responses and fungal control during cryptococcal infection, the role of cDC1
Xu, J., Hissong, R., Bareis, R., Creech, A., Goughenour, K. D., Freeman, C. M., & Olszewski, M. A. (2024) · mBio · doi:10.1128/mbio.02853-23 · Cited by 16
A dendritic cell multitasks to tackle cancer
Burbage, M., & Amigorena, S. (2020) · Nature · doi:10.1038/d41586-020-02339-9 · Cited by 17
Altered ratio of dendritic cell subsets in skin-draining lymph nodes promotes Th2-driven contact hypersensitivity
Miller, H. L., Andhey, P. S., Swiecki, M. K., Rosa, B. A., Zaitsev, K., Villani, A., Mitreva, M., Artyomov, M. N., Gilfillan, S., Cella, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021364118 · Cited by 17
P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target
Zaongo, S. D., Liu, Y., Harypursat, V., Song, F., Xia, H., Ma, P., & Chen, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710121 · Cited by 17
Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State
Bourque, J., & Hawiger, D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100932 · Cited by 17
Noncanonical functions of T follicular helper cells
Dave, S., & Ballesteros‐Tato, A. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr1052 · Cited by 16
The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies
Zhu, W., Fan, C., Zhao, Y., Li, W., Niu, J., Dong, S., Yang, Z., & Zhou, W. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03980-y · Cited by 17
Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity
Xie, B., Yuan, B., Zhao, X., Xie, T., Li, R., Wei, P., Sun, Q., Hu, W., Pan, B., Chen, Y., et al. (2025) · Science · doi:10.1126/science.ady5362 · Cited by 16
Erythropoietin receptor on cDC1s dictates immune tolerance
Zhang, X., McGinnis, C. S., Yu, G., Chen, S., Zheng, P., Schürch, C. M., Hiam-Galvez, K. J., Reticker-Flynn, N. E., Guo, W., Yao, W., et al. (2025) · Nature · doi:10.1038/s41586-025-09824-z · Cited by 17
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Zheng, H., Yu, X., Ibrahim, M. L., Foresman, D., Xie, M., Johnson, J., Boyle, T. A., Ruffell, B., Perez, B. A., Antonia, S. J., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0927 · Cited by 17
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
Wong, J. L., Smith, P., Angulo-Lozano, J. C., Ranti, D. L., Bochner, B. H., Sfakianos, J. P., Horowitz, A., Ravetch, J. V., & Knorr, D. A. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306782120 · Cited by 16
Targeting circulating tumor cells to prevent metastases
Gostomczyk, K., Marsool, M. D. M., Tayyab, H., Pandey, A., Borowczak, J., Macome, F., Chacón, J. A., Dave, T., Maniewski, M., & Szylberg, Ł. (2023) · Human Cell · doi:10.1007/s13577-023-00992-6 · Cited by 16
Single-cell transcriptomics reveals the role of antigen presentation in liver metastatic breast cancer
Wang, X., Zhou, Y., Wu, Z., Xie, C., Xu, W., Zhou, Q., Yang, D., Zhu, D., Wang, M., & Wang, L. (2024) · iScience · doi:10.1016/j.isci.2024.108896 · Cited by 15
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells
Ng, I.-I., Zhang, J., Tian, T., Qi, P., Huang, Z., Xiao, K., Yao, X., Ng, L., Zeng, J., & Tang, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008254 · Cited by 17
Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
D’Amico, C., Fusciello, M., Hamdan, F., D’Alessio, F., Bottega, P., Saklauskaite, M., Russo, S., Cerioni, J., Elbadri, K., Kemell, M., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.11.006 · Cited by 16
Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
Brightman, S. E., Naradikian, M. S., Thota, R. R., Becker, A., Montero, L., Bahmanof, M., Premlal, A. L. R., Greenbaum, J., Peters, B., Cohen, E. E. W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.165570 · Cited by 17
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Schmid, D., Sobottka, B., Manzo, M., Trüb, M., Leonards, K., Herzig, P., Oyewole, O. R.-A., Jermann, P. M., Hayoz, S., Prince, S. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63696-5 · Cited by 17
Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo
Bourque, J., & Hawiger, D. (2022) · Antibodies · doi:10.3390/antib11010008 · Cited by 14
Harnessing the reverse cholesterol transport pathway to favor differentiation of monocyte-derived APCs and antitumor responses
Raccosta, L., Marinozzi, M., Costantini, S., Maggioni, D., Ferreira, L. M., Corna, G., Zordan, P., Sorice, A., Farinello, D., Bianchessi, S., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05620-7 · Cited by 15
Human dendritic cell subsets in the glioblastoma-associated microenvironment
Hu, X., Jiang, C., Gao, Y., & Xue, X. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578147 · Cited by 15
Alloreactive memory CD4 T cells promote transplant rejection by engaging DCs to induce innate inflammation and CD8 T cell priming
Saha, I., Chawla, A. S., Oliveira, A. P. B. N., Elfers, E. E., Warrick, K. A., Meibers, H. E., Jain, V. G., Hagan, T., Katz, J. D., & Pasare, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2401658121 · Cited by 16
Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells
Zou, D., Xin, X., Xu, Y., Xu, H., Huang, L., & Xu, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36446 · Cited by 16
Type I interferon signaling in dendritic cells limits direct antigen presentation and CD8 + T cell responses against an arthritogenic alphavirus
Bullock, C. B., Wang, L., Ware, B. C., Wagoner, N., Ohara, R. A., Liu, T., Desai, P., Peters, B., MURPHY, K. M. M., Handley, S. A., et al. (2024) · mBio · doi:10.1128/mbio.02930-24 · Cited by 16
Molecular basis for chemokine recognition and activation of XCR1
Zhang, X., Schlimgen, R. R., Singh, S., Tomani, M., Volkman, B. F., & Zhang, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405732121 · Cited by 15
ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection
Arabpour, M., Lebrero‐Fernández, C., Schön, K., Strömberg, A., Börjesson, V., Lahl, K., Ballegeer, M., Saelens, X., Angeletti, D., Agace, W. W., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00510-1 · Cited by 15
On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer
Park, M. D., Belabed, M., Chen, S. T., Hamon, P., Hegde, S., Mattiuz, R., Marron, T. U., & Mérad, M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-085949 · Cited by 15
I-Ag7 β56/57 polymorphisms regulate non-cognate negative selection to CD4+ T cell orchestrators of type 1 diabetes
Stadinski, B. D., Cleveland, S. B., Brehm, M. A., Greiner, D. L., Huseby, P. G., & Huseby, E. S. (2023) · Nature Immunology · doi:10.1038/s41590-023-01441-0 · Cited by 15
A tetravalent nanovaccine that inhibits growth of HPV-associated head and neck carcinoma via dendritic and T cell activation
Josi, R., Speiser, D. E., de Brot, S., Vogt, A. S., Sevick-Muraca, E. M., Tolstonog, G. V., Bachmann, M. F., & Mohsen, M. O. (2024) · iScience · doi:10.1016/j.isci.2024.109439 · Cited by 14
Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state
Bersier, L., Lorenzo‐Martín, L. F., Chiang, Y.-H., Durot, S., Czauderna, A., Yarahmadov, T., Wyss, T., Roçi, I., Kim, J., Zamboni, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67169-7 · Cited by 15
Intestinal cDC1s provide cues required for CD4+ T cell–mediated resistance to Cryptosporidium
Cohn, I. S., Wallbank, B. A., Haskins, B. E., O’Dea, K. M., Pardy, R. D., Shaw, S., Merolle, M. I., Gullicksrud, J. A., Christian, D. A., Striepen, B., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232067 · Cited by 14
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity
Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J. K., Bao, Y., Gondal, M. N., Tien, J. C.-Y., Maj, T., Yazdani, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48931-9 · Cited by 14
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A
Lahoud, M. H., & Radford, K. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1873056 · Cited by 14
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
Dendritic cells control tertiary lymphoid structure development and maintenance in cancer
Mattiuz, R., Boumelha, J., Aerakis, E., Bérichel, J. L., Hamon, P., Halász, L., Vaidya, A. B., Soong, B. Y., Radkevich, E., Kim, H. M., et al. (2026) · Science · doi:10.1126/science.ady1678 · Cited by 40
Combined targeting of CCL7 and Flt3L to promote the expansion and infiltration of cDC1s in tumors enhances T-cell activation and anti-PD-1 therapy effectiveness in NSCLC
Dong, H., Li, Y., Tang, Z., Wang, P., Zhong, B., Chu, Q., & Lin, D. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00991-5 · Cited by 13
Unlocking Dendritic Cell-Based Vaccine Efficacy through Genetic Modulation—How Soon Is Now?
Elwakeel, A., Bridgewater, H. E., & Bennett, J. (2023) · Genes · doi:10.3390/genes14122118 · Cited by 13
Dendritic Cells and the Establishment of Fetomaternal Tolerance for Successful Human Pregnancy
Mahajan, D., Kumar, T., Rath, P. K., Sahoo, A. K., Mishra, B. P., Kumar, S., Nayak, N. R., & Jena, M. K. (2024) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.2478/aite-2024-0010 · Cited by 14
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies
Stagg, J., & Gutkind, J. S. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080852 · Cited by 13
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
Gandhi, S., Slomba, R. T., Janes, C., Fitzpatrick, V., Miller, J., Attwood, K. M., Ioannou, G., Ozbey, S., Souza, I. D., Roudko, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010058 · Cited by 15
Harnessing TH9 cells in cancer immunotherapy
Benoit-Lizon, I., & Apétoh, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101477 · Cited by 14
Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
Rafia, C., Harly, C., & Scotet, E. (2020) · Immunological Reviews · doi:10.1111/imr.12920 · Cited by 14
Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 13
Dendritic cell vaccines: Current research progress, challenges, and opportunities
Zhang, S., Mo, S., Huang, W., Zhong, D., Yang, X., Xie, S., Liu, A., Mo, F., Huang, X., Liu, H., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101913 · Cited by 15
Dendritic cells: the central partner for cancer immunity
Laoubi, L., Gobbini, É., Duplouye, P., Hubert, M., Caux, C., Bendriss‐Vermare, N., Valladeau‐Guilemond, J., & Voissière, A. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2571773 · Cited by 12

Authors: Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., Li, L., Gillanders, W. E., Wu, G. F., Yokoyama, W. M., Murphy, T. L., Schreiber, R. D., & Murphy, K. M.
Affiliations: Washington University in St. Louis (US)
University of California, San Francisco (US)
Barnes-Jewish Hospital (US)
Howard Hughes Medical Institute (US)
Corresponding author: Murphy, Kenneth M.
ORCID: Ferris, Stephen T.
Durai, Vivek
Wu, Renee
Theisen, Derek J.
Ward, Jeffrey P.
Bern, Michael D.
Davidson, Jesse T.
Bagadia, Prachi
Liu, Tiantian
Briseño, Carlos G.
Li, Lijin
Gillanders, William E.
Wu, Gregory F.
Yokoyama, Wayne M.
Murphy, Theresa L.
Schreiber, Robert D.
Murphy, Kenneth M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-08-12
Volume: 584
Issue: 7822
Pages: 624-629
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2611-3
PMC: PMC7469755
OpenAlex: W3048641542
Cited by: 611
References: 50
Citations by year: 2026: 112 · 2025: 105 · 2024: 112 · 2023: 127 · 2022: 76 · 2021: 67 · 2020: 12
FWCI: 24.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health (UL1TR000448, UL1TR002345)
National Cancer Institute (T32CA009573, R01CA190700, T32CA009621, R01CA248919, P30CA091842)
National Institute of Allergy and Infectious Diseases (R01AI150297, R01AI129545, T32AI007163, R01AI162643)
National Institute of Diabetes and Digestive and Kidney Diseases (F30DK108498, F30DK112466)
National Institute of Neurological Disorders and Stroke (R01NS106289)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: conventional type 1 dendritic cells, cDC1, CD4+ T cell priming, CD8+ T cell priming, MHC class II, MHC class I, cross-presentation, tumor rejection, antitumor immunity
MeSH terms: Animals, Histocompatibility Antigens Class II, Dendritic Cells, Female, Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, CD40 Antigens, Cross-Priming, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks